Pfizer: The Covid Reset Makes Sense


  • Since the Cominarty vaccine is now arguably relegated to something similar to the seasonal flu shot with an expensive $130 retail price tag, it is unsurprising Mr. Market is bearish on the PFE stock.
  • The generic Paxlovid may also temper some of its top-line, as witnessed with AbbVie’s Humira, which experienced a -25.9% impact in the international market.
  • However, the COVID-19 windfall has also contributed to its robust balance sheet and aggressive M&A activities, bolstering its pipelines ahead.
  • Therefore, assuming an upward rerating, PFE could hit our price target of $55.79, suggesting a 27.40% upside potential from current levels.

Button Reset


The Covid Reset Is Right – Though Overly Pessimistic

With the worst of the COVID-19 pandemic now over, Pfizer Inc (NYSE:PFE) may have a challenging 2023 indeed. The stock had already retraced by -19.6% since its recent peak in mid-December 2022, nearing

PFE 1Y EV/Revenue and P/E Valuations

S&P Capital IQ

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.

Leave a Reply

Your email address will not be published. Required fields are marked *